Lineage Cell Therapeutics Inc (LCTX)
1.14
0.00 (0.00%)
USD |
NYAM |
Apr 23, 16:00
1.14
0.00 (0.00%)
After-Hours: 20:00
Lineage Cell Therapeutics Net Income (TTM): -21.49M for Dec. 31, 2023
Net Income (TTM) Chart
Historical Net Income (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | -21.49M |
| September 30, 2023 | -23.06M |
| June 30, 2023 | -22.02M |
| March 31, 2023 | -23.56M |
| December 31, 2022 | -26.27M |
| September 30, 2022 | -48.91M |
| June 30, 2022 | -50.66M |
| March 31, 2022 | -48.69M |
| December 31, 2021 | -43.02M |
| September 30, 2021 | -12.00M |
| June 30, 2021 | -11.93M |
| March 31, 2021 | -13.67M |
| December 31, 2020 | -20.65M |
| September 30, 2020 | -27.16M |
| June 30, 2020 | -35.91M |
| March 31, 2020 | -59.42M |
| December 31, 2019 | -11.71M |
| September 30, 2019 | -52.18M |
| June 30, 2019 | 31.05M |
| March 31, 2019 | 56.87M |
| December 31, 2018 | -45.99M |
| September 30, 2018 | -72.97M |
| June 30, 2018 | -125.38M |
| March 31, 2018 | -132.81M |
| December 31, 2017 | -19.98M |
| Date | Value |
|---|---|
| September 30, 2017 | 46.88M |
| June 30, 2017 | 63.76M |
| March 31, 2017 | 99.96M |
| December 31, 2016 | 33.56M |
| September 30, 2016 | 25.21M |
| June 30, 2016 | -19.61M |
| March 31, 2016 | -53.85M |
| December 31, 2015 | -46.91M |
| September 30, 2015 | -44.07M |
| June 30, 2015 | -38.71M |
| March 31, 2015 | -38.54M |
| December 31, 2014 | -36.47M |
| September 30, 2014 | -45.50M |
| June 30, 2014 | -46.23M |
| March 31, 2014 | -44.26M |
| December 31, 2013 | -43.88M |
| September 30, 2013 | -30.31M |
| June 30, 2013 | -26.26M |
| March 31, 2013 | -24.17M |
| December 31, 2012 | -21.42M |
| September 30, 2012 | -20.75M |
| June 30, 2012 | -19.53M |
| March 31, 2012 | -18.35M |
| December 31, 2011 | -16.74M |
| September 30, 2011 | -14.35M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (TTM) Range, Past 5 Years
-59.42M
Minimum
Mar 2020
31.05M
Maximum
Jun 2019
-27.43M
Average
-23.56M
Median
Mar 2023
Net Income (TTM) Benchmarks
| Acumen Pharmaceuticals Inc | -52.37M |
| Sarepta Therapeutics Inc | -535.98M |
| CEL-SCI Corp | -31.05M |
| AIM ImmunoTech Inc | -28.96M |
| IGC Pharma Inc | -14.14M |